{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T13:59:33Z","timestamp":1765807173691,"version":"3.40.5"},"reference-count":42,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.pupt.2014.04.009","type":"journal-article","created":{"date-parts":[[2014,5,16]],"date-time":"2014-05-16T12:02:22Z","timestamp":1400241742000},"page":"91-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Comparative mortality risk of tiotropium administered via handihaler or respimat in COPD patients: Are they equivalent?"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4675-9616","authenticated-orcid":false,"given":"Alexander G.","family":"Mathioudakis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Chatzimavridou-Grigoriadou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Efstathia","family":"Evangelopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios A.","family":"Mathioudakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos M.","family":"Siafakas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2014","series-title":"Management and prevention of COPD, global initiative for chronic obstructive lung disease (GOLD)","author":"From the Global Strategy for the Diagnosis","key":"10.1016\/j.pupt.2014.04.009_bib1"},{"issue":"15","key":"10.1016\/j.pupt.2014.04.009_bib2","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1056\/NEJMoa0805800","article-title":"A\u00a04-year trial of tiotropium in chronic obstructive pulmonary disease","volume":"359","author":"Tashkin","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.pupt.2014.04.009_bib3","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1056\/NEJMoa1008378","article-title":"Tiotropium versus salmeterol for the prevention of exacerbations of COPD","volume":"364","author":"Vogelmeier","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.pupt.2014.04.009_bib4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1164\/rccm.200707-973OC","article-title":"The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol\/fluticasone propionate or tiotropium bromide","volume":"177","author":"Wedzicha","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.pupt.2014.04.009_bib5","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1378\/chest.12-2613","article-title":"Treadmill endurance during 2-year treatment with tiotropium in patients with COPD: a randomised trial","volume":"144","author":"Cooper","year":"2013","journal-title":"Chest"},{"issue":"11\u201312","key":"10.1016\/j.pupt.2014.04.009_bib6","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/0024-3205(95)00020-7","article-title":"Tiotropium bromide (Ba 679 BR), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease","volume":"56","author":"Barnes","year":"1995","journal-title":"Life Sci"},{"issue":"12","key":"10.1016\/j.pupt.2014.04.009_bib7","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1001\/jama.300.12.1439","article-title":"Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis","volume":"300","author":"Singh","year":"2008","journal-title":"J\u00a0Am Med Assoc"},{"issue":"5","key":"10.1016\/j.pupt.2014.04.009_bib8","first-page":"481","article-title":"Tiotropium and the risk of death in COPD","volume":"370","author":"Verhamme","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"1\u20132","key":"10.1016\/j.pupt.2014.04.009_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2004.06.018","article-title":"A\u00a0review of the development of respimat soft mist inhaler","volume":"283","author":"Dalby","year":"2004","journal-title":"Int J Pharm"},{"issue":"1","key":"10.1016\/j.pupt.2014.04.009_bib10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1089\/jamp.2012.1012","article-title":"Tiotropium handihaler improves the survival of patients with COPD: a systematic review and meta-analysis","volume":"27","author":"Mathioudakis","year":"2014","journal-title":"J\u00a0Aerosol Med Pulm Drug Deliv"},{"issue":"9308","key":"10.1016\/j.pupt.2014.04.009_bib11","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0140-6736(02)07882-0","article-title":"Sample size slippages in randomised trials: exclusions and the lost and wayward","volume":"359","author":"Schulz","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.pupt.2014.04.009_bib12","article-title":"What proportion of chronic obstructive pulmonary disease outpatients is eligible for inclusion in randomized clinical trials?","author":"Scichilone","year":"2013","journal-title":"Respiration"},{"issue":"16","key":"10.1016\/j.pupt.2014.04.009_bib13","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa1303342","article-title":"Tiotropium Respimat inhaler and the risk of death in COPD","volume":"369","author":"Wise","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.pupt.2014.04.009_bib14","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1056\/NEJMp1008502","article-title":"The safety of tiotropium\u2013the FDA's conclusions","volume":"363","author":"Michele","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.pupt.2014.04.009_bib15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1378\/chest.09-0011","article-title":"Cardiovascular safety of tiotropium in patients with COPD","volume":"137","author":"Celli","year":"2010","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.pupt.2014.04.009_bib16","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1378\/chest.12-2613","article-title":"Treadmill endurance during 2-year treatment with tiotropium in patients with COPD: a randomized trial","volume":"144","author":"Cooper","year":"2013","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.pupt.2014.04.009_bib17","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1378\/chest.11-0038","article-title":"The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting \u03b2-agonist therapy in COPD","volume":"141","author":"Short","year":"2012","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.pupt.2014.04.009_bib18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.pupt.2011.10.004","article-title":"Tiotropium handihaler and the risk of cardio- or cerebrovascular events and mortality in patients with COPD","volume":"25","author":"Verhamme","year":"2012","journal-title":"Pulm Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.pupt.2014.04.009_bib19","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1157\/13110735","article-title":"Calculation of morbidity, use of resources and costs of patients treated with tiotropium bromide for COPD in a Spanish population","volume":"39","author":"Sicras-Mainar","year":"2007","journal-title":"Aten Primaria"},{"issue":"1","key":"10.1016\/j.pupt.2014.04.009_bib20","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.rmed.2007.08.009","article-title":"A\u00a0randomized study of tiotropium respimat soft mist inhaler vs. ipratropium pMDI in COPD","volume":"102","author":"Voshaar","year":"2008","journal-title":"Respir Med"},{"key":"10.1016\/j.pupt.2014.04.009_bib21","article-title":"Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease","author":"Hohlfeld","year":"2013","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.pupt.2014.04.009_bib22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.rmed.2009.11.011","article-title":"Tiotropium 5microg via Respimat and 18 microg via HandiHaler; efficacy and safety in Japanese COPD patients","volume":"104","author":"Ichinose","year":"2010","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.pupt.2014.04.009_bib23","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.rmed.2008.10.002","article-title":"The efficacy of tiotropium administered via respimat soft mist inhaler or handihaler in COPD patients","volume":"103","author":"van Noord","year":"2009","journal-title":"Respir Med"},{"issue":"16","key":"10.1016\/j.pupt.2014.04.009_bib24","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa1303342","article-title":"Tiotropium respimat inhaler and the risk of death in COPD","volume":"369","author":"Wise","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.pupt.2014.04.009_bib25","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.rmed.2013.02.005","article-title":"Safety and efficacy of the once-daily anticholinergic BEA2180 compared\u00a0with tiotropium in patients with COPD","volume":"107","author":"Abrahams","year":"2013","journal-title":"Respir Med"},{"key":"10.1016\/j.pupt.2014.04.009_bib26","first-page":"197","article-title":"Efficacy and safety of tiotropium respimat SMI in COPD in two 1-year randomized studies","volume":"5","author":"Bateman","year":"2010","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"10","key":"10.1016\/j.pupt.2014.04.009_bib27","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.rmed.2010.06.004","article-title":"A\u00a0one-year trial of tiotropium respimat plus usual therapy in COPD patients","volume":"104","author":"Bateman","year":"2010","journal-title":"Respir Med"},{"key":"10.1016\/j.pupt.2014.04.009_bib28","unstructured":"NCT01040403: Determining Optimal Free Dose Combination of Tiotropium Bromide and BI 1744 CL in Chronic Obstructive Pulmonary Disease (COPD)."},{"key":"10.1016\/j.pupt.2014.04.009_bib29","doi-asserted-by":"crossref","first-page":"d3215","DOI":"10.1136\/bmj.d3215","article-title":"Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials","volume":"342","author":"Singh","year":"2011","journal-title":"Br Med J"},{"key":"10.1016\/j.pupt.2014.04.009_bib30","first-page":"CD009285","article-title":"Tiotropium versus placebo for chronic obstructive pulmonary disease","volume":"7","author":"Karner","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.pupt.2014.04.009_bib31","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1183\/09031936.00042113","article-title":"Tiotropium respimat increases the risk of mortality: pro","volume":"42","author":"Beasley","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2014.04.009_bib32","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/thoraxjnl-2012-201926","article-title":"Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials","volume":"68","author":"Dong","year":"2013","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.pupt.2014.04.009_bib33","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1183\/09031936.00042213","article-title":"Tiotropium respimat increases the risk of mortality: con","volume":"42","author":"Bateman","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2014.04.009_bib34","doi-asserted-by":"crossref","first-page":"e7390","DOI":"10.1136\/bmj.e7390","article-title":"Call for worldwide withdrawal of tiotropium respimat mist inhaler","volume":"345","author":"Beasley","year":"2012","journal-title":"Br Med J"},{"issue":"4","key":"10.1016\/j.pupt.2014.04.009_bib35","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1164\/rccm.201204-0596PP","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary","volume":"187","author":"Vestbo","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2014.04.009_bib36","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1465-9921-14-40","article-title":"The Tiotropium Safety and Performance in Respimat Trial (TIOSPIR), a large scale, randomized, controlled, parallel-group trial-design and rationale","volume":"14","author":"Wise","year":"2013","journal-title":"Respir Res"},{"issue":"5","key":"10.1016\/j.pupt.2014.04.009_bib37","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1056\/NEJMc1314411","article-title":"Tiotropium and the risk of death in COPD","volume":"370","author":"Loke","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.pupt.2014.04.009_bib38","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1183\/09031936.00005813","article-title":"Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patients with COPD","volume":"42","author":"Verhamme","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2014.04.009_bib39","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jamainternmed.2013.1016","article-title":"Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease","volume":"173","author":"Gershon","year":"2013","journal-title":"JAMA Intern Med"},{"issue":"5","key":"10.1016\/j.pupt.2014.04.009_bib40","first-page":"481","article-title":"Tiotropium and the risk of death in COPD","volume":"370","author":"Verhamme","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.pupt.2014.04.009_bib41","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1089\/jamp.2012.0988","article-title":"Tiotropium inhaler devices: seeking convenience when mortality is at stake?","volume":"26","author":"Mathioudakis","year":"2013","journal-title":"J\u00a0Aerosol Med Pulm Drug Deliv"},{"year":"2013","series-title":"Summary of Product Characteristics (SPC): Spiriva Respimat 2.5 microgram solution for inhalation. eMC","key":"10.1016\/j.pupt.2014.04.009_bib42"}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553914000480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553914000480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T10:54:45Z","timestamp":1565434485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553914000480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S1094553914000480"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2014.04.009","relation":{},"ISSN":["1094-5539"],"issn-type":[{"type":"print","value":"1094-5539"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative mortality risk of tiotropium administered via handihaler or respimat in COPD patients: Are they equivalent?","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2014.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}